Therapeutic approaches for control of transcription factors in allergic disease

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 4, 2008, Pages 803-809

  Cousins, David J ^a   McDonald, Joanne ^a   Lee, Tak H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

asthma; atopic dermatitis; GATA3; glucocorticoid receptor; nuclear factor B; nuclear factor of activated T cells; signal transducer and activator of transcription 6; TH2; Transcription factors

Indexed keywords

CYCLOSPORIN A; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; STAT6 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NFAT;

ALLERGIC DISEASE; ASTHMA; ATOPIC DERMATITIS; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TH2 CELL;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION; TH2 CELLS; TRANSCRIPTION FACTORS;

EID: 41449107295     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.02.008     Document Type: Review

References (101)

1. Larche M., Robinson D.S., and Kay A.B. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 111 (2003) 450-463
2. Ngoc P.L., Gold D.R., Tzianabos A.O., Weiss S.T., and Celedon J.C. Cytokines, allergy, and asthma. Curr Opin Allergy Clin Immunol 5 (2005) 161-166
3. Wynn T.A. IL-13 effector functions. Annu Rev Immunol 21 (2003) 425-456
4. Hirst S.J., Martin J.G., Bonacci J.V., Chan V., Fixman E.D., Hamid Q.A., et al. Proliferative aspects of airway smooth muscle. J Allergy Clin Immunol 114 suppl (2004) S2-S17
5. Ansel K.M., Djuretic I., Tanasa B., and Rao A. Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol 24 (2006) 607-656
6. Mowen K.A., and Glimcher L.H. Signaling pathways in Th2 development. Immunol Rev 202 (2004) 203-222
7. Cousins D.J., Lee T.H., and Staynov D.Z. Cytokine coexpression during human TH1/TH2 cell differentiation: direct evidence for coordinated expression of th2 cytokines. J Immunol 169 (2002) 2498-2506
8. Gilmour J., Cousins D.J., Richards D.F., Sattar Z., Lee T.H., and Lavender P. Regulation of GM-CSF expression by the transcription factor c-Maf. J Allergy Clin Immunol 120 (2007) 56-63
9. Messi M., Giacchetto I., Nagata K., Lanzavecchia A., Natoli G., and Sallusto F. Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol 4 (2003) 78-86
10. Santangelo S., Cousins D.J., Winkelmann N.E., and Staynov D.Z. DNA methylation changes at human Th2 cytokine genes coincide with DNase I hypersensitive site formation during CD4(+) T cell differentiation. J Immunol 69 (2002) 1893-1903
11. Kaplan M.H., Schindler U., Smiley S.T., and Grusby M.J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4 (1996) 313-319
12. Shimoda K., van Deursen J., Sangster M.Y., Sarawar S.R., Carson R.T., Tripp R.A., et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380 (1996) 630-633
13. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., et al. Essential role of Stat6 in IL-4 signalling. Nature 380 (1996) 627-630
14. Akimoto T., Numata F., Tamura M., Takata Y., Higashida N., Takashi T., et al. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med 187 (1998) 1537-1542
15. Kuperman D., Schofield B., Wills-Karp M., and Grusby M.J. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 187 (1998) 939-948
16. Yokozeki H., Ghoreishi M., Takagawa S., Takayama K., Satoh T., Katayama I., et al. Signal transducer and activator of transcription 6 is essential in the induction of contact hypersensitivity. J Exp Med 191 (2000) 995-1004
17. Yokozeki H., Wu M.H., Sumi K., Awad S., Satoh T., Katayama I., et al. In vivo transfection of a cis element "decoy" against signal transducers and activators of transcription 6 (STAT6)-binding site ameliorates IgE-mediated late-phase reaction in an atopic dermatitis mouse model. Gene Ther 11 (2004) 1753-1762
18. Kuperman D.A., Huang X., Koth L.L., Chang G.H., Dolganov G.M., Zhu Z., et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 8 (2002) 885-889
19. Mathew A., MacLean J.A., DeHaan E., Tager A.M., Green F.H., and Luster A.D. Signal transducer and activator of transcription 6 controls chemokine production and T helper cell type 2 cell trafficking in allergic pulmonary inflammation. J Exp Med 193 (2001) 1087-1096
20. Hoshino A., Tsuji T., Matsuzaki J., Jinushi T., Ashino S., Teramura T., et al. STAT6-mediated signaling in Th2-dependent allergic asthma: critical role for the development of eosinophilia, airway hyper-responsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation. Int Immunol 16 (2004) 1497-1505
21. Hill S., Herlaar E., Le Cardinal A., van Heeke G., and Nicklin P. Homologous human and murine antisense oligonucleotides targeting stat6. Functional effects on germline cepsilon transcript. Am J Respir Cell Mol Biol 21 (1999) 728-737
22. Peng Q., Matsuda T., and Hirst S.J. Signaling pathways regulating interleukin-13-stimulated chemokine release from airway smooth muscle. Am J Respir Crit Care Med 169 (2004) 596-603
23. Rippmann J.F., Schnapp A., Weith A., and Hobbie S. Gene silencing with STAT6 specific siRNAs blocks eotaxin release in IL-4/TNFalpha stimulated human epithelial cells. FEBS Lett 579 (2005) 173-178
24. Stolzenberger S., Haake M., and Duschl A. Specific inhibition of interleukin-4-dependent Stat6 activation by an intracellularly delivered peptide. Eur J Biochem 268 (2001) 4809-4814
25. McCusker C.T., Wang Y., Shan J., Kinyanjui M.W., Villeneuve A., Michael H., et al. Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. J Immunol 179 (2007) 2556-2564
26. Zheng W., and Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89 (1997) 587-596
27. Lee H.J., Takemoto N., Kurata H., Kamogawa Y., Miyatake S., O'Garra A., et al. GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp Med 192 (2000) 105-116
28. Sundrud M.S., Grill S.M., Ni D., Nagata K., Alkan S.S., Subramaniam A., et al. Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J Immunol 171 (2003) 3542-3549
29. Pai S.Y., Truitt M.L., and Ho I.C. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. Proc Natl Acad Sci U S A 101 (2004) 1993-1998
30. Zhu J., Min B., Hu-Li J., Watson C.J., Grinberg A., Wang Q., et al. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat Immunol 5 (2004) 1157-1165
31. Skapenko A., Leipe J., Niesner U., Devriendt K., Beetz R., Radbruch A., et al. GATA-3 in human T cell helper type 2 development. J Exp Med 199 (2004) 423-428
32. Lee G.R., and Flavell R.A. Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol 16 (2004) 1155-1160
33. Nakamura Y., Christodoulopoulos P., Cameron L., Wright E., Lavigne F., Toda M., et al. Upregulation of the transcription factor GATA-3 in upper airway mucosa after in vivo and in vitro allergen challenge. J Allergy Clin Immunol 105 (2000) 1146-1152
34. Nakamura Y., Ghaffar O., Olivenstein R., Taha R.A., Soussi-Gounni A., Zhang D.H., et al. Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol 103 (1999) 215-222
35. Kiwamoto T., Ishii Y., Morishima Y., Yoh K., Maeda A., Ishizaki K., et al. Transcription factors T-bet and GATA-3 regulate development of airway remodeling. Am J Respir Crit Care Med 174 (2006) 142-151
36. Yamashita N., Tashimo H., Ishida H., Matsuo Y., Tamauchi H., Terashima M., et al. Involvement of GATA-3-dependent Th2 lymphocyte activation in airway hyperresponsiveness. Am J Physiol Lung Cell Mol Physiol 290 (2006) L1045-L1051
37. Finotto S., De Sanctis G.T., Lehr H.A., Herz U., Buerke M., Schipp M., et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 193 (2001) 1247-1260
38. Lee C.C., Huang H.Y., and Chiang B.L. Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness. Mol Ther 16 (2008) 60-65
39. Maneechotesuwan K., Xin Y., Ito K., Jazrawi E., Lee K.Y., Usmani O.S., et al. Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol 178 (2007) 2491-2498
40. Duan W., Chan J.H., McKay K., Crosby J.R., Choo H.H., Leung B.P., et al. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 171 (2005) 571-578
41. Underwood D.C., Osborn R.R., Kotzer C.J., Adams J.L., Lee J.C., Webb E.F., et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 293 (2000) 281-288
42. Hogan P.G., Chen L., Nardone J., and Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17 (2003) 2205-2232
43. Crabtree G.R., and Olson E.N. NFAT signaling: choreographing the social lives of cells. Cell 109 suppl (2002) S67-S79
44. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 5 (2005) 472-484
45. Peng S.L., Gerth A.J., Ranger A.M., and Glimcher L.H. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity 14 (2001) 13-20
46. Ponticelli C., Tarantino A., Campise M., Montagnino G., Aroldi A., and Passerini P. From cyclosporine to the future. Transplant Proc 36 suppl (2004) 557S-560S
47. Fonacier L., Spergel J., Charlesworth E.N., Weldon D., Beltrani V., Bernhisel-Broadbent J., et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 115 (2005) 1249-1253
48. Corrigan C.J. Asthma refractory to glucocorticoids: the role of newer immunosuppressants. Am J Respir Med 1 (2002) 47-54
49. Khan L.N., Kon O.M., Macfarlane A.J., Meng Q., Ying S., Barnes N.C., et al. Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin. Am J Respir Crit Care Med 162 (2000) 1377-1382
50. Hersperger R., Buchheit K.H., Cammisuli S., Enz A., Lohse O., Ponelle M., et al. A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma. J Med Chem 47 (2004) 4950-4957
51. Bechstein W.O. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 13 (2000) 313-326
52. Olyaei A.J., de Mattos A.M., and Bennett W.M. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 7 (2001) 384-389
53. Noguchi H., Matsushita M., Okitsu T., Moriwaki A., Tomizawa K., Kang S., et al. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med 10 (2004) 305-309
54. Roehrl M.H., Kang S., Aramburu J., Wagner G., Rao A., and Hogan P.G. Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci U S A 101 (2004) 7554-7559
55. Venkatesh N., Feng Y., DeDecker B., Yacono P., Golan D., Mitchison T., et al. Chemical genetics to identify NFAT inhibitors: potential of targeting calcium mobilization in immunosuppression. Proc Natl Acad Sci U S A 101 (2004) 8969-8974
56. Aramburu J., Yaffe M.B., Lopez-Rodriguez C., Cantley L.C., Hogan P.G., and Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285 (1999) 2129-2133
57. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8 (2007) 49-62
58. Bureau F., Delhalle S., Bonizzi G., Fievez L., Dogne S., Kirschvink N., et al. Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. J Immunol 165 (2000) 5822-5830
59. Gagliardo R., Chanez P., Mathieu M., Bruno A., Costanzo G., Gougat C., et al. Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med 168 (2003) 1190-1198
60. Hart L.A., Krishnan V.L., Adcock I.M., Barnes P.J., and Chung K.F. Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med 158 (1998) 1585-1592
61. Poynter M.E., Irvin C.G., and Janssen-Heininger Y.M. Rapid activation of nuclear factor-kappaB in airway epithelium in a murine model of allergic airway inflammation. Am J Pathol 160 (2002) 1325-1334
62. Yang L., Cohn L., Zhang D.H., Homer R., Ray A., and Ray P. Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. J Exp Med 188 (1998) 1739-1750
63. Donovan C.E., Mark D.A., He H.Z., Liou H.C., Kobzik L., Wang Y., et al. NF-kappa B/Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation. J Immunol 163 (1999) 6827-6833
64. Das J., Chen C.H., Yang L., Cohn L., Ray P., and Ray A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2 (2001) 45-50
65. Barton D., HogenEsch H., and Weih F. Mice lacking the transcription factor RelB develop T cell-dependent skin lesions similar to human atopic dermatitis. Eur J Immunol 30 (2000) 2323-2332
66. Weih F., Warr G., Yang H., and Bravo R. Multifocal defects in immune responses in RelB-deficient mice. J Immunol 158 (1997) 5211-5218
67. Shiina T., Konno A., Oonuma T., Kitamura H., Imaoka K., Takeda N., et al. Targeted disruption of MAIL, a nuclear IkappaB protein, leads to severe atopic dermatitis-like disease. J Biol Chem 279 (2004) 55493-55498
68. Yamamoto M., Yamazaki S., Uematsu S., Sato S., Hemmi H., Hoshino K., et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature 430 (2004) 218-222
69. Choi I.W., Kim D.K., Ko H.M., and Lee H.K. Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappaB inhibits established asthmatic reaction in mice. Int Immunopharmacol 4 (2004) 1817-1828
70. Desmet C., Gosset P., Pajak B., Cataldo D., Bentires-Alj M., Lekeux P., et al. Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol 173 (2004) 5766-5775
71. Henderson Jr. W.R., Chi E.Y., Teo J.L., Nguyen C., and Kahn M. A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol 169 (2002) 5294-5299
72. Huang T.J., Adcock I.M., and Chung K.F. A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat. Br J Pharmacol 134 (2001) 1029-1036
73. Chapoval S.P., Al-Garawi A., Lora J.M., Strickland I., Ma B., Lee P.J., et al. Inhibition of NF-κB activation reduces the tissue effects of transgenic IL-13. J Immunol 179 (2007) 7030-7041
74. Adcock I.M., Ito K., and Barnes P.J. Glucocorticoids: effects on gene transcription. Proc Am Thorac Soc 1 (2004) 247-254
75. Newton R., and Holden N.S. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?. Mol Pharmacol 72 (2007) 799-809
76. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353 (2005) 1711-1723
77. Kassel O., Sancono A., Kratzschmar J., Kreft B., Stassen M., and Cato A.C. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 20 (2001) 7108-7116
78. Lasa M., Abraham S.M., Boucheron C., Saklatvala J., and Clark A.R. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 22 (2002) 7802-7811
79. Mizuno H., Uemura K., Moriyama A., Wada Y., Asai K., Kimura S., et al. Glucocorticoid induced the expression of mRNA and the secretion of lipocortin 1 in rat astrocytoma cells. Brain Res 746 (1997) 256-264
80. Biola A., Andreau K., David M., Sturm M., Haake M., Bertoglio J., et al. The glucocorticoid receptor and STAT6 physically and functionally interact in T-lymphocytes. FEBS Lett 487 (2000) 229-233
81. Ray A., and Prefontaine K.E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A 91 (1994) 752-756
82. Schule R., Rangarajan P., Kliewer S., Ransone L.J., Bolado J., Yang N., et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62 (1990) 1217-1226
83. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995) 286-290
84. Jee Y.K., Gilmour J., Kelly A., Bowen H., Richards D., Soh C., et al. Repression of interleukin-5 transcription by the glucocorticoid receptor targets GATA3 signaling and involves histone deacetylase recruitment. J Biol Chem 280 (2005) 23243-23250
85. Smith P.J., Cousins D.J., Jee Y.K., Staynov D.Z., Lee T.H., and Lavender P. Suppression of granulocyte-macrophage colony-stimulating factor expression by glucocorticoids involves inhibition of enhancer function by the glucocorticoid receptor binding to composite NF-AT/activator protein-1 elements. J Immunol 167 (2001) 2502-2510
86. Ito K., Barnes P.J., and Adcock I.M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 20 (2000) 6891-6903
87. Lowenberg M., Verhaar A.P., Bilderbeek J., Marle J., Buttgereit F., Peppelenbosch M.P., et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 7 (2006) 1023-1029
88. Smoak K., and Cidlowski J.A. Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. Mol Cell Biol 26 (2006) 9126-9135
89. Jing Q., Huang S., Guth S., Zarubin T., Motoyama A., Chen J., et al. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120 (2005) 623-634
90. Chivers J.E., Gong W., King E.M., Seybold J., Mak J.C., Donnelly L.E., et al. Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol 70 (2006) 2084-2095
91. Schacke H., Schottelius A., Docke W.D., Strehlke P., Jaroch S., Schmees N., et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 101 (2004) 227-232
92. Belvisi M.G., Wicks S.L., Battram C.H., Bottoms S.E., Redford J.E., Woodman P., et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 166 (2001) 1975-1982
93. Schacke H., Berger M., Rehwinkel H., and Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275 (2007) 109-117
94. Glass C.K., and Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6 (2006) 44-55
95. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 53 (2002) 409-435
96. Ricote M., and Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771 (2007) 926-935
97. Ward J.E., and Tan X. Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. PPAR Res 2007 (2007) 14983
98. Woerly G., Honda K., Loyens M., Papin J.P., Auwerx J., Staels B., et al. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 198 (2003) 411-421
99. Staumont-Salle D., Abboud G., Brenuchon C., Kanda A., Roumier T., Lavogiez C., et al. Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol (2008) Feb 13 [epub ahead of print]
100. Nyce J. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease. Curr Opin Allergy Clin Immunol 2 (2002) 533-536
101. Nyce J.W., and Metzger W.J. DNA antisense therapy for asthma in an animal model. Nature 385 (1997) 721-725